Year in Review | Published:

Cervical cancer in 2013

Screening comes of age and treatment progress continues

Nature Reviews Clinical Oncology volume 11, pages 7778 (2014) | Download Citation

In 2013, studies confirmed that HPV infection of target cells predisposes to cervical (pre)cancer. In developed countries, HPV screening revealed superior protection than cytology screening. In India, visual inspection of the cervix after acetic acid application significantly reduced cervical cancer mortality after 12 years. Improved survival for women with advanced disease was observed after adjuvant bevacizumab.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. Cervical squamocolumnar junction-specific markers define distinct, clinically relevant subsets of low-grade squamous intraepithelial lesions. Am. J. Surg. Pathol. 37, 1311–1318 (2013).

  2. 2.

    et al. A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer. Proc. Natl Acad. Sci. USA 109, 10516–10521 (2012).

  3. 3.

    et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet (2013).

  4. 4.

    et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 30 (Suppl. 5), F88–F99 (2012).

  5. 5.

    et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol. 13, 78–88 (2012).

  6. 6.

    et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 11, 249–257 (2010).

  7. 7.

    et al. Effect of visual inspection with acetic acid (VIA) screening by primary health workers on cervical cancer mortality: a cluster randomized controlled trial in Mumbai, India [abstract]. J. Clin. Oncol. 31 (Suppl.), a2 (2013).

  8. 8.

    et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group [abstract]. J. Clin. Oncol. 31 (Suppl.), a3 (2013).

  9. 9.

    From ASCO—Gynaecological cancer: advances in cervical cancer screening and treatment. Nat. Rev. Clin. Oncol. 10, 425 (2013).

Download references

Acknowledgements

This work has been made possible by grants from the European Union: FP7 frame work programme agreement no242061 PREHDICT, and agreement no: 603019 COHEAHR.

Author information

Affiliations

  1. Department of Pathology, Vrije Universiteit Medical Centre Amsterdam, de Boelelaan 1117, 1084 HV Amsterdam, The Netherlands.

    • Chris J. L. M. Meijer
    •  & Peter J. F. Snijders

Authors

  1. Search for Chris J. L. M. Meijer in:

  2. Search for Peter J. F. Snijders in:

Competing interests

C. J. L. M. Meijer and P. J. F. Snijders have minority stock in self-screen, a spin-off company of the Vrije Universiteit in Amsterdam. C. J. L. M. Meijer has been member of the scientific Advisory board of Qiagen and has been occasionally on the Advisory board of GlaxoSmithKline and Roche. P. J. F. Snijders has been occasionally on the Advisory Board of Roche, GlaxoSmithKline and Genprobe.

Corresponding author

Correspondence to Chris J. L. M. Meijer.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrclinonc.2013.252

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing